The Availability Of Other Treatment Options, Such As Drug Therapies And Surgeries, Limits The Growth Of Deep Brain Stimulation Devices Market
The deep brain stimulation (DBS) device, also known as a brain pacemaker, aids in the relief of Parkinson's disease symptoms (PD). The device is implanted at one of three FDA-approved brain sites in the United States to block electrical signals from these sites to the brain. The three FDA-approved targeted brain sites in the United States are the ventrointermedialis (VIM) nucleus of the thalamus, the subthalamic nucleus (STN), and the globus pallidus pars interna (GPi). DBS surgery is performed on patients who have had Parkinson's disease for at least four years and are taking medications, albeit with motor complications. Although there are other surgical options such as Thalamotomy and Pallidotomy, DBS is the preferred option because it does not involve tissue destruction and is a reversible surgical treatment.
The rise in the prevalence of lifestyle diseases such as depression and chronic pain, as well as the rise in the number of neurological disorders and investment in neurological R&D, are driving the growth of the global deep brain stimulation devices market. Furthermore, as the ageing population becomes more susceptible to neurological disorders such as epilepsy, Parkinson's disease, Alzheimer's disease, and chronic pain, the demand for minimally invasive surgery, the adoption of technologically advanced products, and the rise in the ageing population drive the deep brain stimulation devices market growth. The most significant barriers to the growth of the Deep Brain Stimulation Devices Market are side effects such as allergic reactions and tingling or prickling of the skin caused by the implantation of a deep brain stimulation device into the body, as well as an increase in device cost. However, the availability of other treatment options, such as drug therapies and surgeries, limits the market growth of deep brain stimulation devices.
Because of an increase in FDA approvals for deep brain stimulation devices in clinical applications, North America dominated the Deep Brain Stimulation devices market with a share of 51.9 percent in 2020. For example, the FDA in the United States approved Brio, a deep brain stimulation device, in 2015 for the treatment of Parkinson's disease. Furthermore, the region's demand for deep brain stimulation devices is expected to be driven by an increase in the number of patients diagnosed with Parkinson's disease, as well as increased government funding and initiatives to raise awareness about movement disorders.
Comments
Post a Comment